Health Canada Approves Markham-Based Astellas' XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

MARKHAM, ON, Jan. 14, 2020 /CNW/ - Astellas Pharma Canada, Inc., announced that Health Canada has approved the oral once-daily therapy XOSPATA (gilteritinib) for the treatment of adult patients with relapsed (disease that has returned) or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation.

Categorized in: Business, Life Sciences & Health Technology Posted on: January 15, 2020 Last updated on: December 22, 2022 Written by: Nathan Allen

MARKHAM, ON, Jan. 14, 2020 /CNW/ – Astellas Pharma Canada, Inc., announced that Health Canada has approved the oral once-daily therapy XOSPATA (gilteritinib) for the treatment of adult patients with relapsed (disease that has returned) or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib has the potential to improve treatment outcomes for AML patients with two forms of the most common mutation—FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD) mutation.^1,2

Full Article: newswire.ca